XML 21 R65.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Commitments and Contingencies - Additional Information (Detail) | 1 Months Ended | 3 Months Ended | 12 Months Ended | 60 Months Ended |
--- | --- | --- | --- | --- | ---
Jul. 31, 2019 USD ($) | Dec. 31, 2019 USD ($) € / $ | Dec. 31, 2019 EUR (€) | Sep. 30, 2018 USD ($) | Sep. 30, 2024 USD ($) | Sep. 30, 2019 USD ($)
Commitments And Contingencies [Line Items] |  |  |  |  |  |
Exchange rate relating to license payment | € / $ |  | 1.1215 |  |  |  |
Other long-term liabilities |  | $ 6,634,000 |  |  |  | $ 5,512,000
Embolitech LLC [Member] |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |
Contingent payments upon achievement of regulatory milestones |  | $ 2,000,000 |  |  |  |
Installment payment beginning period |  | 2020 | 2020 |  |  |
Installment payment ending period |  | 2024 | 2024 |  |  |
CRO [Member] |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |
Contractual obligation to be paid |  | $ 11,900,000 |  |  |  |
CRO [Member] | Maximum [Member] |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |
Contractual obligations |  | 26,000,000 |  |  |  |
Contractual obligation due in next several years |  | 40,000,000 |  |  |  |
CRO [Member] | Minimum [Member] |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |
Contractual obligation due in next several years |  | $ 35,000,000 |  |  |  |
License [Member] |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |
License agreement commencement date |  | 2006-03 | 2006-03 |  |  |
Annual minimum payments for licenses |  | $ 224,000 | € 200,000 |  |  |
Future minimum payments associated with license |  | $ 1,800,000 |  |  |  |
Patents [Member] |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |
Patent expiry date |  | 2027-09 | 2027-09 |  |  |
Intellectual Property [Member] | Medical Device [Member] |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |
Payments to acquire intellectual property assets | $ 800,000 |  |  |  |  |
Contingent payments upon achievement of regulatory milestones | $ 1,300,000 |  |  |  |  |
Contingency period ending year | 2022 |  |  |  |  |
Estimated additional payment to acquire intellectual property assets | $ 200,000 |  |  |  |  |
Intellectual Property [Member] | Embolitech LLC [Member] |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |
Payments to acquire intellectual property assets |  |  |  | $ 5,000,000 |  |
Contingency period ending year |  | 2033 | 2033 |  |  |
Other accrued liabilities noncurrent |  | $ 1,200,000 |  |  |  | 1,000,000
Other long-term liabilities |  | $ 2,100,000 |  |  |  | $ 2,100,000
Intellectual Property [Member] | Embolitech LLC [Member] | Scenario Forecast [Member] |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |
Estimated additional payment to acquire intellectual property assets |  |  |  |  | $ 3,500,000 |

X
- Definition Annual minimum payments for license. + References No definition available. + Details
Name: | srdx_AnnualMinimumPaymentsForLicense
Namespace Prefix: | srdx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset acquisition contingency period ending year. + References No definition available. + Details
Name: | srdx_AssetAcquisitionContingencyPeriodEndingYear
Namespace Prefix: | srdx_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset acquisition contingent payments upon achievement of regulatory milestones. + References No definition available. + Details
Name: | srdx_AssetAcquisitionContingentPaymentsUponAchievementOfRegulatoryMilestones
Namespace Prefix: | srdx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset acquisition current contingent payments upon achievement of regulatory milestones. + References No definition available. + Details
Name: | srdx_AssetAcquisitionCurrentContingentPaymentsUponAchievementOfRegulatoryMilestones
Namespace Prefix: | srdx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset acquisition installment payment, beginning period. + References No definition available. + Details
Name: | srdx_AssetAcquisitionInstallmentPaymentBeginningPeriod
Namespace Prefix: | srdx_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset acquisition installment payment, ending period. + References No definition available. + Details
Name: | srdx_AssetAcquisitionInstallmentPaymentEndingPeriod
Namespace Prefix: | srdx_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Commitments and contingencies. + References No definition available. + Details
Name: | srdx_CommitmentsAndContingenciesLineItems
Namespace Prefix: | srdx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contractual obligation due. + References No definition available. + Details
Name: | srdx_ContractualObligationDue
Namespace Prefix: | srdx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contractual obligation due in next several years. + References No definition available. + Details
Name: | srdx_ContractualObligationDueInNextSeveralYears
Namespace Prefix: | srdx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Expiration date of patent that is classified as a definite-lived intangible asset. + References No definition available. + Details
Name: | srdx_FiniteLivedIntangibleAssetsUsefulLifeEndDate
Namespace Prefix: | srdx_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition Future annual minimum payments for license. + References No definition available. + Details
Name: | srdx_FutureMinimumAnnualLicenseMaintenanceFeePayable
Namespace Prefix: | srdx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Date upon which the license agreement commenced related to our exclusive right to use the licensed drug delivery coating product. + References No definition available. + Details
Name: | srdx_LicenseAgreementCommencementDate
Namespace Prefix: | srdx_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition Future cash outflow to pay for purchases of fixed assets that have occurred. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586 + Details
Name: | us-gaap_CapitalExpendituresIncurredButNotYetPaid
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments. + References No definition available. + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521 + Details
Name: | us-gaap_ForeignCurrencyExchangeRateTranslation1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.24) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_OtherAccruedLiabilitiesNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.24) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_OtherLiabilitiesNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=srdx_EmbolitechLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=srdx_ClinicalResearchOrganizationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=srdx_MedicalDeviceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |